Posts Tagged ‘Aids Drug’
HIV Market has Strong Competition Between Several Marketed and Combination Products
HIV AIDS – Drug Pipeline Analysis and Market Forecasts to 2016
This report provides the key data, information and analysis on the HIV/AIDS market. The report provides a comprehensive overview of the annualized market data from 2001 to 2009, and forecast seven years to 2016. The research also includes market characterization, opportunities, the unmet needs associated with HIV/AIDS, competitive assessment, the product profiles of the major marketed products and the promising drugs in the pipeline, an overview of the discontinued projects, the implications for prospect market struggle, and the key players in the HIV/AIDS market. ( http://www.bharatbook.com/detail.asp?id=134479&rt=HIV-AIDS-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html )
The HIV/AIDS Therapeutics Market is Forecast to Show Moderate Growth To 2016
This analysis suggests that the global Human Immunodeficiency Virus (HIV)/Bought Immune Deficiency Syndrome (AIDS) market was value $12 billion in 2009. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 2% for the next seven years to reach $13.7 billion by 2016. The global HIV infection market will continue to grow between 2009 and 2016 at a moderate rate due to a series of patent expiries in this period. The growth rate is likely to decline from 2012 onwards due to the impact of patent expiries of key drugs. But, migration to new branded drugs is likely to minimize the impact of generics. This moderate growth will be driven by an increasing prescription rate and augmented usage of newer drugs such as Atripla as part of Highly Active Antiretroviral Therapy (HAART).The number of people taking treatment for HIV is increasing and the average annual cost of therapy for Antiretroviral Treatment (ART) is forecast to increase at a privileged rate over the next two years with an expected price decline from 2012 onwards due to a series of patent expirations. The market is characterized by a high unmet need of drugs in terms of efficacy and drugs which can cure the disease. HAART requires patients to take different classes of drugs and has succeeded in achieving near zero levels of HIV in infected people but. The augmented uptake of HAART and increasing awareness will drive the market. Therefore despite challenges such as the lack of a cure and the risk of building drug resistance to current marketed drugs, the HIV market will continue to grow at a moderate rate.
The HIV Market has Strong Struggle Between Several Marketed and Amalgamation Products
It analyzed the current competitive landscape for HIV/AIDS drugs and found the struggle to be strong. There are more than 30 marketed products from different classes of therapies for the treatment of HIV. But, all these classes of drugs are relatively high on protection but moderate on efficacy. This is because there is no cure for the infection on the market. In addition, some of the new multi-class amalgamation drugs have improved the efficacy in terms of lowering HIV levels in the body. Therefore drugs compete on efficacy in terms of delaying the progression of the disease and amalgamation drugs are considered far better in this regard. The drugs on the market today aim to prolong the time it takes for the HIV infection to become AIDS. This has led to an increase in the average life expectancy of people infected with HIV. Overall, the HIV/AIDS market is in need of products with better efficacy profiles and persons which promise to cure the disease.
The Unmet Need of a Cost Effective Cure is Unlikely to be Fulfilled in the Coming Years
It has found that the global HIV/AIDS market is a highly lucrative market with high levels of unmet need in terms of drug efficacy and curing the disease. The HIV market consists of a generous number of drugs that are approved for HIV but none that can cure the disease. All these drugs need long term usage and the length of the therapy can last approximately 20 years. The HIV drugs on the market are considered safe as the side effects associated with HIV drugs are minimal when compared with the effects of the untreated progression of the disease itself. The disease can be fatal and is associated with many opportunistic infections which decrease the quality of life of the infected person. Therefore, while the unmet need for the HIV market will remain, some newer drugs may offer better treatment for drug-resistance HIV or have better efficacy in terms of lower dosage frequencies to improve patient compliance and improve treatment quality in the coming years.
Strong Clinical Pipeline with Several First-in-Class Molecules
It analyzed the HIV/AIDS pipeline and found it to be strong. The pipeline for HIV consists of more than 250 molecules currently in enhancement for various disease segments. There are many companies active in developing HIV drugs. In addition to the leading market players, Boehring Ingelheim, Achillion Pharmaceuticals, GlaxoSmithKline, Incyte and Pharmasset, Shire Pharmaceuticals and Tibotec Virco are active in developing drugs for the HIV therapeutics market. The pipeline for HIV/AIDS is strong as many pharmaceutical companies today are primarily focusing on the new antiviral agents which offer effective treatment options for patients who no longer respond to existing therapies. As a result, the treatment model for HIV has evolved from monotherapy to triple amalgamation treatment known as HAART. The HIV/AIDS clinical pipeline is strong with several first-in-class molecules in enhancement. Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and protease inhibitors are most well loved drug classes in which most pipeline activity is currently taking place. Overall, there are 101 first-in-class molecules which accounts for 41% of the pipeline. Multi-class amalgamation therapies and me-too products account for approximately 42% of the clinical pipeline and are expected to improve on the protection profiles of marketed drugs.
To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/detail.asp?id=134479&rt=HIV-AIDS-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
Or
Contact us at :
Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Blog: http://bharatbookresearch.blogspot.com
Follow us on twitter: http://twitter.com/3bbharatbook
We are the leading information aggregator, facilitates and supports the business information needs. With over 115,000 reports, you can get instant access and insights on the studies in yo for market research , corporate / strategic plotting by providing the newest information in the form of reports, journals, magazines and databases on varied industries like automotive, oil and gas, shipping, textiles, pharmaceuticals, energy, banking, finance, insurance, risk management, people intelligence, consumer & durable commodities, chemical and more ur areas of appeal. Contact us at +91 22 27578668 / 27579438 or email info@bharatbook.com or our website www.bharatbook.com
Related Blogs
AIDS Pandemic: AIDS, HIV/AIDS in Africa, HIV/AIDS in Asia, HIV/AIDS in Latin America, HIV/AIDS in the Caribbean, HIV/AIDS in Eastern Europe and Central … in the United States, HIV/AIDS in Australia
Product Description
AIDS pandemic. AIDS, HIV/AIDS in Africa, HIV/AIDS in Asia, HIV/AIDS in Latin America, HIV/AIDS in the Caribbean, HIV/AIDS in Eastern Europe and Central Asia, HIV/AIDS in Western Europe, HIV/AIDS in the United States, HIV/AIDS in Australia, HIV/AIDS in Papua New Guinea, Sexually transmitted disease, Scarification, Blood transfusion, AIDS denialism, Intravenous drug use (recreational)… More >>
Related Blogs
HIV/AIDS – Drug Pipeline Analysis and Market Forecasts to 2016-Aarkstore Enterprise
HIV/AIDS – Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global HIV/AIDS market. The report identifies the key trends shaping and driving the global HIV/AIDS market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring noteworthy shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global HIV/AIDS sector. GlobalData estimated the HIV/AIDS market was value $12 billion in 2009. The global Human Immunodeficiency Virus (HIV) infection market will continue to grow between 2009 and 2016 at a slower rate due to a series of patent expiries during this period. The growth rate is likely to decline from 2012 onwards due to the impact of the patent expiry of key drugs. The market is characterized by a high unmet need of drugs which can cure the disease. Highly Active Antiretroviral Therapy (HAART) which requires patients to take different classes of drugs has but succeeded in achieving near zero levels of HIV in infected people. Augmented uptake of HAART and increasing awareness (which leads to augmented treatment seeking) will drive the market. The pipeline for HIV is strong and consists of more than 250 molecules currently in enhancement for various disease segments.
This report is built using data and information sourced from proprietary databases, primary and lesser research and in house analysis by GlobalData’s team of industry experts.
Scope
- Annualized global HIV/AIDS market revenues data from 2001 to 2009, forecast for seven years to 2016.
- Geographies covered in this report are the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing a split across phases by mechanism of action, and the emerging trends. The key classes of mechanism of action include HIV vaccines, Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Multi-class Amalgamation Products, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), CCR5 receptor antagonists, HIV integrase inhibitors, Nucleoside analogues, Viral entry inhibitors, Maturation inhibitors and Fusion Inhibitors.
- Analysis of the current and prospect market struggle in the global HIV/AIDS market. The key market players covered Boehring Ingelheim, Achillion Pharmaceuticals, GlaxoSmithKline, Incyte and Pharmasset, Shire Pharmaceuticals and Tibotec Virco
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- The key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the prospect HIV/AIDS market.
Reasons to buy
The report will enhance your choice building capability in a more rapid and time sensitive manner. It will allocate you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global HIV/AIDS market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global HIV/AIDS market in prospect.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present most opportunities for consolidations, investments and strategic partnerships.
- What’s the next huge thing in the global HIV/AIDS market landscape? – Identify, know and capitalize
For more information, delight contact :
Related Blogs
What is the symbolic and full meaning of the Red Ribbon with a knot in the AIDS disease ?
AIDS and red ribbon with a knot
Related Blogs
- The Knot Collection of Ceremony and Wedding Music Selected by the Knot’s Carley Roney | Best Buy Cheapest Price
- Honey Honey » Red Ribbon Studio : Blog
- HIV/AIDS Symptoms, Transmission, Diagnosis, Prevention and Treatment » Expert analysis of transmission of sexually transmitted AIDS, intravenous drug users to bump up with
AHF Campaign to Save AIDS Treatment in PEPFAR; dolfilms.org
Because of lifesaving AIDS treatment, Jenny Boyce’s children are not orphans. Because of treatment, Lydia’s granddauther Phumla is thriving. Listen to the tales of people living with HIV/AIDS who receive medical care at AIDS Healthcare Foundation’s Ithembalabantu “People’s Hope” Clinic in Durban, South Africa. Treatment has saved their lives and families. – Video Bent by Dream Out Loud Productions
Related Blogs
Zero Patience: A Movie Musical About Aids
Zero Patience: A Movie Musical About Aids
Related Blogs
- HIV/AIDS – Drug Pipeline Analysis and Market Forecasts to 2016-Aarkstore Enterprise | myautomotive
- Flag Watch: Saturday at Rand Corp – Col Gayton and Adm Mullen | RedState
- HIV/AIDS Symptoms, Transmission, Diagnosis, Prevention and Treatment » “Sexual chaos” increase the risk of AIDS, “AIDS Phobia” simple to attack the crowd Kochi
is there a scientific cure for HIV virus in the USA?
I question this because I have a close relative that has the HIV virus and I don’t know if it’s a myth or is it real that in other countries not including the USA, there has been found a cure for the virus. Does anyone know?
Related Blogs
- HIV/AIDS – Drug Pipeline Analysis and Market Forecasts to 2016 | Medicine Introduction Center
- How long does the HIV/ AIDS virus live in the body once a person passes away? | Health Network
- THE TRUTH ABOUT HIV AIDS VIRUS PART 1 | Price Info, Side Effects, Dosage, Compare Cost, Pros & Cons, Reviews by Patients and Customers.
How to Manage AIDS HIV Treatment Side Effects?
The most common side effects associated with the drugs usually used in HIV and AIDS drug treatment are increases in cholesterol, shifts in the way the body stores stout, nausea, faintness, headache and stomach discomfort. Because these side effects can be severe, doctors usually form a strategy to manage them at the outset of the treatment regimen.
Related Blogs
if u were to watch a video on HIV/AIDS awareness what would you want to see/hear on the video?
im doing a video for school on HIV/AIDS awareness and how people can get help & how they can get tested, & i needed help with thoughts on what to place on the video & how to start it.